Cargando…
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
BACKGROUND: Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens containing bedaquiline and/or delamanid. METHODS: Multicentre (16 countries), prospective, observational study reporting incidence...
Autores principales: | Hewison, Catherine, Khan, Uzma, Bastard, Mathieu, Lachenal, Nathalie, Coutisson, Sylvine, Osso, Elna, Ahmed, Saman, Khan, Palwasha, Franke, Molly F, Rich, Michael L, Varaine, Francis, Melikyan, Nara, Seung, Kwonjune J, Adenov, Malik, Adnan, Sana, Danielyan, Narine, Islam, Shirajul, Janmohamed, Aleeza, Karakozian, Hayk, Kamene Kimenye, Maureen, Kirakosyan, Ohanna, Kholikulov, Begimkul, Krisnanda, Aga, Kumsa, Andargachew, Leblanc, Garmaly, Lecca, Leonid, Nkuebe, Mpiti, Mamsa, Shahid, Padayachee, Shrivani, Thit, Phone, Mitnick, Carole D, Huerga, Helena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522425/ https://www.ncbi.nlm.nih.gov/pubmed/35028659 http://dx.doi.org/10.1093/cid/ciac019 |
Ejemplares similares
-
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019) -
Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023) -
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs( )
por: Huerga, Helena, et al.
Publicado: (2022) -
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
por: Patil, S. B., et al.
Publicado: (2023) -
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial
por: Guglielmetti, L., et al.
Publicado: (2021)